<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825939</url>
  </required_header>
  <id_info>
    <org_study_id>WUH 592498-2</org_study_id>
    <nct_id>NCT03825939</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty</brief_title>
  <official_title>Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study aims to study the use of tranexamic acid (TXA) in total joint replacement
      (arthroplasty) of the hip (THR) and knee (TKR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic Acid (TXA) is given to stop or reduce heavy bleeding. It works by stopping clots
      from breaking down and by decreasing unwanted bleeding. It is used in many types of surgeries
      to help reduce surgical complications such as blood loss and blood transfusions.

      In orthopaedic surgeries, such as in total hip and knee replacements, TXA has been shown to
      effectively reduce blood loss and transfusion requirements without an increased risk of side
      effects such as deep venous thrombosis (DVT) or pulmonary embolism (PE). The ability to
      decrease blood loss is crucial, as other studies have shown that reducing blood loss
      decreases morbidity and mortality in patients.

      Although, many TXA dosing regimens have been studied - all of which have been useful at
      reducing blood loss and decreasing transfusion requirements - the best TXA dosing regimen and
      the most cost-effective method of TXA administration for patients have yet to be determined.
      Moreover, a thorough and rigorous study on the use and effects of topical and intravenous TXA
      and the effect of TXA on patient outcomes has yet to be conducted.

      Therefore, this research study aims to address those concerns in order to understand how best
      to use TXA to reduce surgical complications in patients undergoing total joint replacements.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient enrollment due to only one surgeon that was enrolling.
  </why_stopped>
  <start_date type="Actual">April 21, 2015</start_date>
  <completion_date type="Actual">September 6, 2016</completion_date>
  <primary_completion_date type="Actual">July 26, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative transfusion rates</measure>
    <time_frame>Throughout course of hospital stay during postoperative period (an average of 3-4 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss during surgery</measure>
    <time_frame>Operative period (an average of 1 hour)</time_frame>
    <description>Surgeon estimated blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change between pre-operative and subsequent post-operative hemoglobin/hematocrit levels</measure>
    <time_frame>Throughout course of hospital stay during postoperative period (an average of 3-4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with draining wounds</measure>
    <time_frame>Throughout course of hospital stay during postoperative period (an average of 3-4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with venous thromboembolic events</measure>
    <time_frame>Throughout course of hospital stay during postoperative period (an average of 3-4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with infection</measure>
    <time_frame>Throughout course of hospital stay during postoperative period (an average of 3-4 days)</time_frame>
    <description>All patients will be monitored for clinical signs and symptoms of infection
Routine standard of care involves nasal screening for MRSA during the Pre-Anesthesia Testing (PAT), pre-operative surgical site cleansing at home, and pre-operative holding. Patients are maintained on a strict peri-operative antibiotic regimen that follows the SCIPS (Surgical Care Improvement Project National Hospital Inpatient Quality Measures) protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Throughout course of hospital stay during postoperative period (an average of 3-4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Range of motion (degrees)</measure>
    <time_frame>4 days</time_frame>
    <description>Measured throughout hospital stay
Total joint arthroplasty of the knee - Range of motion (degrees) and walking distance (feet) will be assessed and documented throughout the hospital stay Physical therapy function - please see description for more details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking distance post total joint arthroplasty of the hip</measure>
    <time_frame>4 Days</time_frame>
    <description>Walking distance (feet) will be assessed and documented throughout the hospital stay</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g TXA administered intravenous piggyback at start of surgery OR
1g TXA administered intravenous piggyback at start and at time of closure of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental
- Single dose topical TXA (1g/50 mL in 0.9% sterile saline) administered during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>- IV 0.9% sterile saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>- Topical 0.9% sterile saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Tranexamic Acid</intervention_name>
    <description>Topical TXA (1g/10mL in 0.9% sterile saline)</description>
    <arm_group_label>Topical Tranexamic Acid</arm_group_label>
    <other_name>Tranexamic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <description>IV 0.9% sterile saline</description>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Tranexamic Acid</intervention_name>
    <description>1g TXA IVPB</description>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <other_name>Tranexamic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Placebo</intervention_name>
    <description>Topical 0.9% sterile saline</description>
    <arm_group_label>Topical Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  All patients 18 years and older who are already scheduled for primary total joint
             arthroplasty of the hip or knee

        Exclusion Criteria for IV TXA administration

          -  Cardiac stent or ischemic stroke or coronary artery bypass graft (CABG)

          -  If patient is on anticoagulant, patient must have documented approval from a
             cardiologist that patient can be removed from anticoagulant for total joint
             arthroplasty procedure

          -  Renal impairment defined as serum Cr &gt; 1.5 or Cr Clearance &lt; 50 mL/min

          -  Severe ischemic heart disease

          -  Color blindness or problems with color vision

        Criteria for Use of Topical TXA

          -  Topical TXA can be used in any patient meeting one of the exclusion criteria for IV
             TXA administration (Section 5.3b) as there is minimal systemic absorption with topical
             TXA

        Absolute Exclusion Criteria

          -  History of deep vein thrombosis (DVT) or pulmonary embolism (PE)

          -  Known congenital thrombophilia

          -  History of thromboembolic or vascular disease

          -  Disseminated intravascular coagulation (DIC)

          -  History of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan A Koenig, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5.</citation>
    <PMID>17403800</PMID>
  </reference>
  <reference>
    <citation>Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999 Jan;81(1):2-10.</citation>
    <PMID>9973048</PMID>
  </reference>
  <reference>
    <citation>Pedersen AB, Mehnert F, Overgaard S, Johnsen SP. Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study. BMC Musculoskelet Disord. 2009 Dec 29;10:167. doi: 10.1186/1471-2474-10-167.</citation>
    <PMID>20040083</PMID>
  </reference>
  <reference>
    <citation>Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012 May 17;344:e3054. doi: 10.1136/bmj.e3054. Review.</citation>
    <PMID>22611164</PMID>
  </reference>
  <reference>
    <citation>Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 Jan;93(1):39-46. doi: 10.1302/0301-620X.93B1.24984. Review.</citation>
    <PMID>21196541</PMID>
  </reference>
  <reference>
    <citation>Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. Knee. 2013 Oct;20(5):300-9. doi: 10.1016/j.knee.2013.05.014. Epub 2013 Jun 28. Review.</citation>
    <PMID>23815893</PMID>
  </reference>
  <reference>
    <citation>Orpen NM, Little C, Walker G, Crawfurd EJ. Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. Knee. 2006 Mar;13(2):106-10. Epub 2006 Feb 17.</citation>
    <PMID>16487712</PMID>
  </reference>
  <reference>
    <citation>Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005 Jun;76(3):314-9.</citation>
    <PMID>16156456</PMID>
  </reference>
  <reference>
    <citation>Niskanen RO, Korkala OL. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop. 2005 Dec;76(6):829-32.</citation>
    <PMID>16470437</PMID>
  </reference>
  <reference>
    <citation>Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br. 2001 Jul;83(5):702-5.</citation>
    <PMID>11476309</PMID>
  </reference>
  <reference>
    <citation>Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion. 2008 Mar;48(3):519-25. Epub 2007 Dec 7.</citation>
    <PMID>18067499</PMID>
  </reference>
  <reference>
    <citation>Camarasa MA, Ollé G, Serra-Prat M, Martín A, Sánchez M, Ricós P, Pérez A, Opisso L. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth. 2006 May;96(5):576-82. Epub 2006 Mar 10.</citation>
    <PMID>16531440</PMID>
  </reference>
  <reference>
    <citation>Chang CH, Chang Y, Chen DW, Ueng SW, Lee MS. Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty. Clin Orthop Relat Res. 2014 May;472(5):1552-7. doi: 10.1007/s11999-013-3446-0. Epub 2014 Jan 3.</citation>
    <PMID>24385043</PMID>
  </reference>
  <reference>
    <citation>Martin JG, Cassatt KB, Kincaid-Cinnamon KA, Westendorf DS, Garton AS, Lemke JH. Topical administration of tranexamic acid in primary total hip and total knee arthroplasty. J Arthroplasty. 2014 May;29(5):889-94. doi: 10.1016/j.arth.2013.10.005. Epub 2013 Oct 16.</citation>
    <PMID>24238825</PMID>
  </reference>
  <reference>
    <citation>Georgiadis AG, Muh SJ, Silverton CD, Weir RM, Laker MW. A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty. J Arthroplasty. 2013 Sep;28(8 Suppl):78-82. doi: 10.1016/j.arth.2013.03.038. Epub 2013 Jul 29.</citation>
    <PMID>23906869</PMID>
  </reference>
  <reference>
    <citation>Konig G, Hamlin BR, Waters JH. Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty. J Arthroplasty. 2013 Oct;28(9):1473-6. doi: 10.1016/j.arth.2013.06.011. Epub 2013 Jul 23.</citation>
    <PMID>23886406</PMID>
  </reference>
  <reference>
    <citation>Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. J Arthroplasty. 2014 Feb;29(2):387-9. doi: 10.1016/j.arth.2013.05.026. Epub 2013 Jun 21.</citation>
    <PMID>23790499</PMID>
  </reference>
  <reference>
    <citation>Gilbody J, Dhotar HS, Perruccio AV, Davey JR. Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty. 2014 Apr;29(4):681-4. doi: 10.1016/j.arth.2013.09.005. Epub 2013 Oct 4.</citation>
    <PMID>24095586</PMID>
  </reference>
  <reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </reference>
  <reference>
    <citation>Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2013 Jan;471(1):150-4. doi: 10.1007/s11999-012-2488-z.</citation>
    <PMID>22814857</PMID>
  </reference>
  <reference>
    <citation>Fu DJ, Chen C, Guo L, Yang L. Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Traumatol. 2013;16(2):67-76.</citation>
    <PMID>23540893</PMID>
  </reference>
  <reference>
    <citation>Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012 Jul 3;94(13):1153-9. doi: 10.2106/JBJS.K.00873.</citation>
    <PMID>22623147</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total hip arthroplasty</keyword>
  <keyword>Total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

